$ILMN earnings report

Illumina reported Q3 2026 revenue of $1,129 million, GAAP diluted EPS of $1.43, and raised fiscal year 2026 revenue and non-GAAP diluted EPS guidance excluding tariff refunds. AlphAI read Illumina's Third quarter of fiscal year 2026 filing as solid. 2 quarters are on record below.

Third quarter of fiscal year 2026

AlphAI · Earnings readILMN · Third quarter of fiscal year 2026 · ended September 27, 2026

Illumina reported Q3 2026 revenue of $1,129 million, GAAP diluted EPS of $1.43, and raised fiscal year 2026 revenue and non-GAAP diluted EPS guidance excluding tariff refunds.

✓Solid quarter

Revenue increased 4.2%, GAAP operating margin expanded to 27.0% from 21.0%, operating cash flow increased to $419 million from $284 million, and the company raised full-year revenue and non-GAAP diluted EPS guidance. Reported results also include IEEPA tariff-refund impacts.

Revenue
$946M
Gross margin · GAAP
73.5%
EPS · non-GAAP
$1.62
Fiscal year 2026, excluding tariff refunds outlook
Total revenue of $4.64-$4.66 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 product revenueGAAP$946M––
Q3 2026 service and other revenueGAAP$183M––
Q3 2026 total revenueGAAP$1.13B–4.2%
Q3 2026 revenue excluding tariff refundsnon-GAAP$1.17B–7.6%
Q3 2026 organic revenue growthnon-GAAP4.8%–4.8%
Q3 2026 ROW organic revenue growthnon-GAAP4.7%–4.7%
Q3 2026 cost of product revenueGAAP$199M––
Q3 2026 cost of service and other revenueGAAP$82M––
Q3 2026 amortization of acquired intangible assetsGAAP$18M––
Q3 2026 total cost of revenueGAAP$299M––
Q3 2026 gross profitGAAP$830M––
Q3 2026 gross marginGAAP73.5%––
Q3 2026 non-GAAP gross profitnon-GAAP$850M––
Q3 2026 non-GAAP gross marginnon-GAAP75.3%––
Q3 2026 non-GAAP gross profit excluding tariff refundsnon-GAAP$809M––
Q3 2026 non-GAAP gross margin excluding tariff refundsnon-GAAP69.4%––
Q3 2026 research and development expenseGAAP$244M––
Q3 2026 selling, general and administrative expenseGAAP$281M––
Q3 2026 total operating expenseGAAP$525M––
Q3 2026 operating profitGAAP$305M––
Q3 2026 operating marginGAAP27.0%––
Q3 2026 non-GAAP operating profitnon-GAAP$325M––
Q3 2026 non-GAAP operating marginnon-GAAP28.8%––
Q3 2026 non-GAAP operating profit excluding tariff refundsnon-GAAP$292M––
Q3 2026 non-GAAP operating margin excluding tariff refundsnon-GAAP25.0%––
Q3 2026 other expense, netGAAP−$41M––
Q3 2026 income before income taxesGAAP$264M––
Q3 2026 provision for income taxesGAAP$44M––
Q3 2026 net incomeGAAP$220M––
Q3 2026 basic EPSGAAP$1.46––
Q3 2026 diluted EPSGAAP$1.43––
Q3 2026 non-GAAP diluted EPSnon-GAAP$1.62––
Q3 2026 non-GAAP diluted EPS excluding tariff refundsnon-GAAP$1.44––
Q3 2026 cash flow provided by operationsGAAP$419M––
Q3 2026 purchases of property and equipmentGAAP−$41M––
Q3 2026 free cash flownon-GAAP$378M––
Q3 2026 depreciation and amortization expenseGAAP$71M––
Nine months ended September 27, 2026 total revenueGAAP$3.38B–6.2%
Nine months ended September 27, 2026 product revenueGAAP$2.85B––
Nine months ended September 27, 2026 service and other revenueGAAP$535M––
Nine months ended September 27, 2026 organic revenue growthnon-GAAP4.2%–4.2%
Nine months ended September 27, 2026 ROW organic revenue growthnon-GAAP5.4%–5.4%
Nine months ended September 27, 2026 gross profitGAAP$2.32B––
Nine months ended September 27, 2026 gross marginGAAP68.7%––
Nine months ended September 27, 2026 operating profitGAAP$759M––
Nine months ended September 27, 2026 operating marginGAAP22.5%––
Nine months ended September 27, 2026 net incomeGAAP$561M––
Nine months ended September 27, 2026 diluted EPSGAAP$3.65––
Nine months ended September 27, 2026 non-GAAP diluted EPS excluding tariff refundsnon-GAAP$3.90––
Nine months ended September 27, 2026 cash flow provided by operating activitiesGAAP$909M––
Nine months ended September 27, 2026 free cash flownon-GAAP$791M––

Fiscal year 2026, excluding tariff refunds outlook

  • RevenueTotal revenue of $4.64-$4.66 billion
  • NoteOrganic revenue growth greater than 4%
  • NoteROW organic revenue growth greater than 5%
  • NoteNon-GAAP operating margin of 23.6%
  • NoteNon-GAAP diluted EPS of $5.40-$5.45

What drove it

  • Management cited healthy clinical demand and robust NovaSeq X placements.
  • Revenue excluding tariff refunds was $1.17 billion.
  • The Q3 2026 tariff-refund impact consisted primarily of a $79 million benefit recognized as a reduction to cost of revenue and a reduction to revenue of $37 million for refunds expected to be credited to customers.
  • Q3 2026 acquisition-related costs consisted primarily of amortization of intangible assets of $18 million, amortization of inventory fair value step-up for SomaLogic of $2 million, expenses for the SomaLogic and GRAIL acquisitions of $5 million, and net gains on contingent consideration liabilities of $(11) million.
  • Q3 2026 transformational initiatives consisted primarily of implementation costs to upgrade the ERP system.

Concerns

  • The company remains subject to uncertainty from its inclusion on China’s Unreliable Entities List.
  • The filing cites uncertainty regarding tariffs, related court proceedings or administrative actions, and potential additional refund or relief programs.
  • GAAP other expense, net was $(41) million in Q3 2026, compared with $(7) million in Q3 2025.
  • The company cited risks related to order volume, timing and mix, competitive products, manufacturing, third-party suppliers, reimbursement, regulatory clearance, and litigation or liabilities related to previous acquisitions.

What to watch

  • Execution against fiscal year 2026 total revenue guidance of $4.64-$4.66 billion excluding tariff refunds.
  • Delivery of organic revenue growth greater than 4% and ROW organic revenue growth greater than 5%.
  • Whether non-GAAP operating margin reaches 23.6% excluding tariff refunds.
  • Clinical demand and NovaSeq X placements.
  • The ongoing revenue and cost effects of tariff refunds and the portion expected to be credited to customers.
  • China-related operating conditions following the company’s inclusion on China’s Unreliable Entities List.

Balance sheet and cash flow

  • Cash and cash equivalents were $1,289 million at September 27, 2026.
  • Short-term investments were $48 million at September 27, 2026.
  • Cash, cash equivalents and short-term investments were $1.34 billion at the close of the quarter.
  • Term debt was $1,789 million at September 27, 2026.
  • Term debt, current portion was — at September 27, 2026.
  • Net cash provided by operating activities was $419 million for Q3 2026, compared to $284 million in the prior year period.
  • Free cash flow was $378 million for Q3 2026, compared to $253 million in the prior year period.

Analysis

Illumina reported Q3 2026 revenue of $1,129 million, compared with $1,084 million in Q3 2025, with reported revenue growth of 4.2%. Product revenue was $946 million versus $927 million, while service and other revenue was $183 million versus $157 million. Revenue excluding tariff refunds was $1.17 billion. The company reported organic revenue growth of 4.8% and ROW organic revenue growth of 4.7%, and management attributed the quarter to healthy clinical demand and robust NovaSeq X placements.

Profitability improved on the reported GAAP basis. Gross margin was 73.5%, compared with 67.6%, and operating margin was 27.0%, compared with 21.0%. The tariff-refund-adjusted non-GAAP gross margin was 69.4%, compared with 69.2%, while tariff-refund-adjusted non-GAAP operating margin was 25.0%, compared with 24.5%. GAAP operating profit was $305 million versus $227 million, and GAAP diluted EPS was $1.43 versus $0.98. Non-GAAP diluted EPS excluding tariff refunds was $1.44, compared with $1.34.

Tariff refunds materially affected reported Q3 results. The company recognized primarily a $79 million benefit as a reduction to cost of revenue and recorded a $37 million reduction to revenue for the portion of refunds expected to be credited to customers. The reconciliation shows a $(41) million effect on non-GAAP gross profit and a $(33) million effect on non-GAAP operating profit. Investors should distinguish the reported GAAP gross margin of 73.5% from the 69.4% non-GAAP gross margin excluding tariff refunds.

Cash generation increased. Cash flow provided by operations was $419 million, compared with $284 million in the prior-year period, and free cash flow was $378 million, compared with $253 million. At quarter-end, Illumina held $1.34 billion in cash, cash equivalents and short-term investments. The company reported $1,789 million of term debt and no current portion of term debt at September 27, 2026.

For fiscal year 2026, excluding tariff refunds, Illumina raised total revenue guidance to $4.64-$4.66 billion from prior guidance of $4.60-$4.64 billion and raised non-GAAP diluted EPS guidance to $5.40-$5.45 from $5.30-$5.40. It maintained organic revenue growth greater than 4%, ROW organic revenue growth greater than 5%, and non-GAAP operating margin guidance of 23.6%. The filing identifies China-related restrictions, tariff uncertainty, order timing and product mix, competition, manufacturing, and regulatory and reimbursement matters as continuing risks.

Management, verbatim

In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full year revenue and earnings guidance.

Jacob Thaysen, Chief Executive Officer of Illumina

As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem. Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes.

Jacob Thaysen, Chief Executive Officer of Illumina

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported operating metrics were not provided.
  • Segment revenue disclosures were not provided.
  • Capital-return disclosures, including share repurchases and dividends, were not provided.
  • Fiscal year 2026 gross-margin, operating-expense, and tax-rate guidance were not provided.
  • A prior-release outlook section was not provided; therefore, no actual-versus-prior-guidance comparisons are included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of fiscal year 2026

AlphAI · Earnings readILMN · second quarter of fiscal year 2026 · ended June 28, 2026

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

✓Strong quarter

Q2 revenue increased to $ 1,159 million from $ 1,059 million, GAAP operating margin expanded to 21.1% from 20.2%, and the company raised fiscal year 2026 revenue and non-GAAP diluted EPS guidance. Operating cash flow and free cash flow were below the prior-year period, while non-GAAP gross margin and operating margin declined year over year.

Revenue
$1.16B
up 9.5% from Q2 2025 y/y
Product revenue
$982M
Gross margin · GAAP
66.4%
EPS · non-GAAP
$ 1.31
fiscal year 2026 outlook
$4.60-$4.64 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$1.16B–up 9.5% from Q2 2025
ROW organic revenue growthotherup 8.1% excluding the impacts of currency, acquisitions, and China–up 8.1%
Gross profitGAAP$770M––
Gross marginGAAP66.4%––
Gross marginnon-GAAP68.2%––
Income from operationsGAAP$245M––
Operating profitnon-GAAP$260M––
Operating marginGAAP21.1%––
Operating marginnon-GAAP22.5%––
Other income (expense), netGAAP$15M––
Income before income taxesGAAP$260M––
Provision for income taxesGAAP$53M––
Net incomeGAAP$207M––
Basic EPSGAAP$ 1.37––
Diluted EPSGAAP$ 1.35––
Diluted EPSnon-GAAP$ 1.31––
Shares used in computing earnings per share: BasicGAAP151M––
Shares used in computing earnings per share: DilutedGAAP153M––
Cash flow provided by operationsGAAP$201M––
Capital expenditures for free cash flow purposesother$39M––
Free cash flownon-GAAP$162M––
Depreciation and amortization expenseGAAP$70M––
Total revenue, six months ended June 28, 2026GAAP$2.25B––
Gross profit, six months ended June 28, 2026GAAP$1.49B––
Income from operations, six months ended June 28, 2026GAAP$454M––
Net income, six months ended June 28, 2026GAAP$340M––
Diluted EPS, six months ended June 28, 2026GAAP$ 2.22––
Net cash provided by operating activities, six months ended June 28, 2026GAAP$490M––
Net cash used in investing activities, six months ended June 28, 2026GAAP−488M––

Segments

SegmentRevenueq/qy/y
Product revenueNo segment-specific driver was reported.$982M––
Service and other revenueNo segment-specific driver was reported.$177M––

fiscal year 2026 outlook

  • Revenue$4.60-$4.64 billion
  • NoteROW organic revenue growth greater than 5%
  • NoteNon-GAAP operating margin of 23.4%-23.6%
  • NoteNon-GAAP diluted EPS of $5.30-$5.40

What drove it

  • Management said momentum continued to build through the first half of 2026 as technology enabled clinical customers to expand sequencing-intensive applications.
  • Management said demand for NovaSeq X remained high.
  • Management cited expanding workflow and multiomics capabilities as broadening the value of Illumina’s ecosystem.
  • Product revenue was $ 982 million, compared with $ 912 million in the prior-year quarter.
  • Service and other revenue was $ 177 million, compared with $ 147 million in the prior-year quarter.

Concerns

  • GAAP net income was $ 207 million, compared with $ 235 million in the prior-year quarter.
  • GAAP diluted EPS was $ 1.35, compared with $ 1.49 in the prior-year quarter.
  • Non-GAAP gross margin was 68.2%, compared with 69.4% in the prior-year quarter.
  • Non-GAAP operating margin was 22.5%, compared with 23.8% in the prior-year quarter.
  • Cash flow provided by operations was $201 million, compared with $234 million in the prior-year period.
  • Free cash flow was $162 million, compared with $204 million in the prior-year period.
  • The company identified uncertainty regarding its inclusion on China’s Unreliable Entities List, tariffs and trade protection measures, and integration of the SomaLogic Business among its risks.

What to watch

  • Fiscal year 2026 total revenue guidance of $4.60-$4.64 billion.
  • Fiscal year 2026 ROW organic revenue growth guidance greater than 5%.
  • Fiscal year 2026 non-GAAP operating margin guidance of 23.4%-23.6%.
  • Fiscal year 2026 non-GAAP diluted EPS guidance of $5.30-$5.40.
  • Demand for NovaSeq X and adoption of workflow and multiomics capabilities.
  • Operating cash flow and free cash flow following the year-over-year declines in Q2.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 1,040 million at June 28, 2026; $ 1,418 million at December 28, 2025.
  • Short-term investments: 128 million at June 28, 2026; 215 million at December 28, 2025.
  • Cash, cash equivalents and short-term investments: $1.17 billion at the close of the quarter.
  • Accounts receivable, net: 764 million at June 28, 2026; 854 million at December 28, 2025.
  • Inventory, net: 629 million at June 28, 2026; 564 million at December 28, 2025.
  • Property and equipment, net: 745 million at June 28, 2026; 759 million at December 28, 2025.
  • Goodwill: 1,284 million at June 28, 2026; 1,113 million at December 28, 2025.
  • Intangible assets, net: 410 million at June 28, 2026; 210 million at December 28, 2025.
  • Total assets: $ 6,650 million at June 28, 2026; $ 6,644 million at December 28, 2025.
  • Term debt, current portion: 500 million at June 28, 2026; 499 million at December 28, 2025.
  • Term debt: 1,491 million at June 28, 2026; 1,490 million at December 28, 2025.
  • Stockholders’ equity: 2,838 million at June 28, 2026; 2,723 million at December 28, 2025.
  • Net cash used in financing activities: (129) million for the three months ended June 28, 2026; (371) million for the three months ended June 29, 2025.

Analysis

Illumina reported Q2 2026 revenue of $ 1,159 million, compared with $ 1,059 million in Q2 2025, and described this as 9.5% growth. The company also reported ROW organic revenue growth of 8.1%, excluding currency, acquisitions, and China. Product revenue was $ 982 million versus $ 912 million, while service and other revenue was $ 177 million versus $ 147 million. Management attributed the period’s momentum to clinical customers expanding sequencing-intensive applications and said NovaSeq X demand remained high.

GAAP gross margin increased to 66.4% from 65.6%, and income from operations increased to $ 245 million from $ 214 million. GAAP operating margin rose to 21.1% from 20.2%. Non-GAAP operating profit increased to $ 260 million from $ 252 million, but non-GAAP gross margin declined to 68.2% from 69.4% and non-GAAP operating margin declined to 22.5% from 23.8%.

Below operating income, other income (expense), net declined to $ 15 million from $ 92 million. Income before income taxes was $ 260 million versus $ 306 million, and net income was $ 207 million versus $ 235 million. GAAP diluted EPS was $ 1.35 compared with $ 1.49, whereas non-GAAP diluted EPS increased to $ 1.31 from $ 1.19. The filing also reported six-month revenue of $ 2,251 million compared with $ 2,100 million and six-month income from operations of $ 454 million compared with $ 378 million.

Cash generation was lower year over year in the quarter. Cash flow provided by operations was $201 million compared with $234 million, capital expenditures for free cash flow purposes were $39 million, and free cash flow was $162 million compared with $204 million. At quarter-end, Illumina held $1.17 billion in cash, cash equivalents and short-term investments. The balance sheet listed term debt, current portion of 500 million and term debt of 1,491 million.

The company raised fiscal year 2026 total revenue guidance to $4.60-$4.64 billion from prior guidance of $4.52-$4.62 billion, raised ROW organic revenue growth guidance to greater than 5% from 2%-4%, and raised non-GAAP diluted EPS guidance to $5.30-$5.40 from $5.15-$5.30. Non-GAAP operating margin guidance of 23.4%-23.6% was unchanged. The key execution items are sustaining NovaSeq X demand and clinical sequencing applications while delivering the guided operating margin amid the stated China, tariff, integration, and competitive risks.

Management, verbatim

Illumina delivered strong results during the second quarter. Momentum continued to build through the first half of 2026, as our technology is enabling clinical customers to expand sequencing-intensive applications. Based on this performance, we are increasing our revenue and earnings guidance for the year.

Jacob Thaysen, Chief Executive Officer of Illumina

Demand for NovaSeq X remains high as we expand our workflow and multiomics capabilities, broadening the value of Illumina’s ecosystem.

Jacob Thaysen, Chief Executive Officer of Illumina

Not in the filing

stated, not guessed
  • Previous outlook section was not separately provided; therefore, vs_prior_guidance is empty.
  • Prior-quarter comparisons for reported metrics were not provided.
  • Segment-level percentage changes were not provided.
  • Segment-specific revenue drivers were not provided.
  • GAAP net income guidance was not provided.
  • GAAP EPS guidance was not provided.
  • Gross margin guidance was not provided.
  • Operating expenses guidance was not provided.
  • Tax-rate guidance was not provided.
  • Share repurchases, dividends, and other capital-return actions were not reported.
  • A full cash-flow statement was not available in the supplied filing text; six-month net cash used in financing activities and ending cash-flow balances were not visible.
  • Non-GAAP net income was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ILMN earnings dates

When is Illumina's next earnings date?
AlphAI has no date for ILMN yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.